<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03969017</url>
  </required_header>
  <id_info>
    <org_study_id>I-CURE VI STUDY</org_study_id>
    <nct_id>NCT03969017</nct_id>
  </id_info>
  <brief_title>Combination Treatment of NAs and Peg IFN α-2b for Hepatitis B Related, Compensatory Cirrhosis Patients</brief_title>
  <official_title>Combination Treatment of Nucleoside （Acid）Analogue (NAs) and Pegylated Interferon α-2b for NAs Treated, Hepatitis B Related, Compensatory Cirrhosis Patients With Low Level Hepatitis b Virus Surface Antigen (HBsAg)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to demonstrate that whether treatment of nucleoside （acid）analogues (NAs) plus
      pegylated interferon (Peg IFN) α-2b for those NAs treated, low level of HBsAg, hepatitis B
      related compensatory cirrhosis patients will result in higher HBsAg clearance rate and reduce
      the risk of liver cancer. The investigators plan to enroll about 84 hepatitis B related
      compensatory cirrhosis patients, who have received NAs treatment more than 1 year with the
      level of HBsAg &lt;1000IU/ml. These participants will be devided into 2 groups. Group A will
      receive the treatment of NAs plus Peg IFNα-2b. Group B will be treated with NAs as before
      enrollment. The participants in both groups will be followed up for 96 weeks.

      The primary endpoint is to compare the clearance rate of HBsAg between two groups. The
      secondary endpoint includes: (1) comparing the incidence of liver cancer during the 96 weeks
      follow-up, (2) comparing adverse side effects between the 2 groups. (3) comparing the
      virological and biochemical responses between the 2 groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clearance of hepatitis B virus surface antigen (HBsAg) is considered to be the ultimate
      therapeutic goal for hepatitis B patients, for it is related with low incidence of fibrosis
      and liver cancer. The investigators' previous study show that nucleoside （acid）analogues
      (NAs) treated, non-cirrhosis hepatitis B patients switched to /or combined with pegylated
      interferon (Peg IFN)α-2b could obtain a higher HBsAg clearance rate. Hence, the
      investigators' hypothesis is that treatment of NAs plus Peg IFNα-2b for those NAs treated,
      low level of HBsAg, hepatitis B related compensatory cirrhosis patients result in higher
      HBsAg clearance rate and reduce the risk of liver cancer.

      The investigators plan to enroll about 84 hepatitis B related compensatory cirrhosis
      patients, who have received NAs treatment more than 1 year with the level of HBsAg
      &lt;1000IU/ml. These participants will be devided into 2 groups according to their wishes. Group
      A will receive the treatment of NAs (patients previously treated with telbivudine will be
      changed to entecavir) plus Peg IFNα-2b （180ug per week, the dose will be changed to 135ug or
      90ug per week during the treatment if patients could not tolerate the side effects of Peg
      IFNα-2b）. Peg IFNα-2b treatment will be performed until HBsAg &lt;0.05IU/ml, with a maximum
      duration of 48 weeks. Group B will be treated with NAs as before enrollment. The participants
      in both groups will be followed up for 96 weeks.

      The primary endpoint is to compare the clearance rate of HBsAg between two groups. The
      secondary endpoint includes: (1) comparing the incidence of liver cancer during the 96 weeks
      follow-up, (2) comparing adverse side effects, such as ascites, gastrointestinal bleeding,
      encephalopathy, hepatorenal syndrome between the 2 groups. (3) comparing the virological and
      biochemical responses between the 2 groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Anticipated">May 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The clearance rate of HBsAg for both groups during 96 weeks.</measure>
    <time_frame>96 weeks</time_frame>
    <description>The clearance rate of HBsAg will be compared between 2 groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of liver cancer for both groups during 96 weeks</measure>
    <time_frame>96 weeks</time_frame>
    <description>The incidence of liver cancer will be compared between 2 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurance rate of adverse side effects in both groups</measure>
    <time_frame>96 weeks</time_frame>
    <description>Adverse side effects, such as ascites, gastrointestinal bleeding, encephalopathy, hepatorenal syndrome will be compared between 2 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of liver functions in both groups</measure>
    <time_frame>96 weeks</time_frame>
    <description>The levels of alanine transaminase, glutamic-oxalacetic transaminase, albumin, total bilirubin, INR will be compared between the 2 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of blood routine test indexes in both groups</measure>
    <time_frame>96 weeks</time_frame>
    <description>The levels of WBC, Hb, PLT will be compared between the 2 groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Cirrhosis of Liver Due to Hepatitis B (Disorder)</condition>
  <arm_group>
    <arm_group_label>NAs+Peg IFN Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NAs+Peg IFN Group will receive the treatment of NAs (patients previously treated with telbivudine will be changed to entecavir) plus pegylated interferon (Peg IFN)α-2b.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAs Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>NAs Group will be treated with NAs as before enrollment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon (Peg IFN)α-2b</intervention_name>
    <description>Participants in NAs+Peg IFN Group will be treated by Peg IFNα-2b （180ug per week, the dose will be changed to 135ug or 90ug per week during the treatment if patients could not tolerate the side effects of Peg IFNα-2b). Peg IFNα-2b treatment will be performed until HBsAg &lt;0.05IU/ml, with a maximum duration of 48 weeks.</description>
    <arm_group_label>NAs+Peg IFN Group</arm_group_label>
    <other_name>Pi Gebin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nucleoside （acid）analogue (NAs)</intervention_name>
    <description>Both of NAs Group and NAs+Peg IFN Group will be treated with NAs as before enrollment.</description>
    <arm_group_label>NAs Group</arm_group_label>
    <arm_group_label>NAs+Peg IFN Group</arm_group_label>
    <other_name>Boludine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 16-65 years old; Clinical diagnosis of compensatory cirrhosis; Child-Pugh grade
             A; Positive serum hepatitis B surface antigen (HBsAg); HBsAg titer &lt; 1000IU/ml;
             Treated by nucleoside （acid）analogues (NAs) more than 1 year; HBV DNA &lt;20 IU/ml;
             Negative serum hepatitis B e antigen (HBeAg); 15 minutes retention rate of indocyanine
             green &lt;10%; The blood routine examination:
             4×10e9/L＜WBC＜10×10e9/L、100×10e9/L＜PLT＜300×10e9/L.

        Exclusion Criteria:

          -  Treated by interferon within half a year; Drug induce liver diseases; Autoimmune liver
             diseases; Liver diseases caused by metabolic factors; Superinfection with hepatitis A,
             C, D, E viruses; Infected by HIV virus; Severe respiratory diseases; Severe
             circulatory diseases, ; Severe digestive diseases; Severe neurological diseases; Need
             for immunosuppressive therapy for other diseases; Need for radiotherapy/chemotherapy
             for other diseases; Thyroid diseases; Rheumatic diseases; Malignant tumors; Severe
             varicose esophageal and gastric fundus veins; Mental or psychological disorders;
             Alcohol or drug abusers (average alcohol consumption &gt;40g/d for men, &gt;20g/d for
             women); With contraindications to interferon therapy; Pregnancy or having pregnancy
             plan in 3 years; Lactation; Can not comply with the study protocol; Fail to sign the
             informed consent; Other conditions that are not suitable for enrollment determined by
             researchers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bingliang Lin, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bingliang Lin, Doctor</last_name>
    <phone>86-020-85253165</phone>
    <email>lamikin@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Junfeng Chen, Master</last_name>
    <phone>86-020-85253165</phone>
    <email>mountainchen@139.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Third Affliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Bingliang, MD</last_name>
      <phone>86-20-85253165</phone>
      <email>lamikin@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008 Feb;48(2):335-52. Epub 2007 Dec 4. Review.</citation>
    <PMID>18096267</PMID>
  </reference>
  <reference>
    <citation>Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007 Feb;45(2):507-39. Erratum in: Hepatology. 2007 Jun;45(6):1347.</citation>
    <PMID>17256718</PMID>
  </reference>
  <reference>
    <citation>Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009 Feb 14;373(9663):582-92. doi: 10.1016/S0140-6736(09)60207-5.</citation>
    <PMID>19217993</PMID>
  </reference>
  <reference>
    <citation>Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, Slavin J, Bowden S, Gane EJ, Abbott W, Lau GK, Lewin SR, Visvanathan K, Desmond PV, Locarnini SA. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology. 2010 Jun;51(6):1933-44. doi: 10.1002/hep.23571.</citation>
    <PMID>20512987</PMID>
  </reference>
  <reference>
    <citation>Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, Levy M, Locarnini SA. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol. 2010 Apr;52(4):508-13. doi: 10.1016/j.jhep.2010.01.007. Epub 2010 Feb 16.</citation>
    <PMID>20206400</PMID>
  </reference>
  <reference>
    <citation>Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, Wang LY, You SL, Hsiao CK, Yang HI, Chen CJ. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol. 2013 May;58(5):853-60. doi: 10.1016/j.jhep.2012.12.006. Epub 2012 Dec 13.</citation>
    <PMID>23246508</PMID>
  </reference>
  <reference>
    <citation>Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, Chen DS, Kao JH. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology. 2011 Aug;141(2):517-25, 525.e1-2. doi: 10.1053/j.gastro.2011.04.046. Epub 2011 Apr 28.</citation>
    <PMID>21672542</PMID>
  </reference>
  <reference>
    <citation>Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D; BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006 Mar 9;354(10):1001-10.</citation>
    <PMID>16525137</PMID>
  </reference>
  <reference>
    <citation>Hou JL, Gao ZL, Xie Q, Zhang JM, Sheng JF, Cheng J, Chen CW, Mao Q, Zhao W, Ren H, Tan DM, Niu JQ, Chen SJ, Pan C, Tang H, Wang H, Mao YM, Jia JD, Ning Q, Xu M, Wu SM, Li J, Zhang XX, Ji Y, Dong J, Li J. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial. J Viral Hepat. 2015 Feb;22(2):85-93. doi: 10.1111/jvh.12313. Epub 2014 Sep 22.</citation>
    <PMID>25243325</PMID>
  </reference>
  <reference>
    <citation>Moucari R, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, Dauvergne A, Cardoso AC, Asselah T, Nicolas-Chanoine MH, Vidaud M, Valla D, Bedossa P, Marcellin P. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol. 2009 Jun;50(6):1084-92. doi: 10.1016/j.jhep.2009.01.016. Epub 2009 Mar 9.</citation>
    <PMID>19376603</PMID>
  </reference>
  <reference>
    <citation>Dietary effects on diurnal variation in lipogenesis. Nutr Rev. 1987 May;45(5):157-8.</citation>
    <PMID>3601258</PMID>
  </reference>
  <reference>
    <citation>Chevaliez S, Hézode C, Bahrami S, Grare M, Pawlotsky JM. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol. 2013 Apr;58(4):676-83. doi: 10.1016/j.jhep.2012.11.039. Epub 2012 Dec 3.</citation>
    <PMID>23219442</PMID>
  </reference>
  <reference>
    <citation>European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012 Jul;57(1):167-85. doi: 10.1016/j.jhep.2012.02.010. Epub 2012 Mar 20. Erratum in: J Hepatol. 2013 Jan;58(1):201. Janssen, Harry [corrected to Janssen, Harry L A].</citation>
    <PMID>22436845</PMID>
  </reference>
  <reference>
    <citation>Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008 Aug;135(2):459-67. doi: 10.1053/j.gastro.2008.05.031. Epub 2008 May 15.</citation>
    <PMID>18585385</PMID>
  </reference>
  <reference>
    <citation>Moucari R, Boyer N, Ripault MP, Castelnau C, Mackiewicz V, Dauvergne A, Valla D, Vidaud M, Chanoine MH, Marcellin P. Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients. J Viral Hepat. 2011 Aug;18(8):580-6. doi: 10.1111/j.1365-2893.2010.01332.x. Epub 2010 May 17.</citation>
    <PMID>20487260</PMID>
  </reference>
  <reference>
    <citation>Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, Sharma BC. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol. 2005 Nov;100(11):2463-71.</citation>
    <PMID>16279901</PMID>
  </reference>
  <reference>
    <citation>Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol. 2014 Oct;61(4):777-84. doi: 10.1016/j.jhep.2014.05.044. Epub 2014 Jun 7.</citation>
    <PMID>24915612</PMID>
  </reference>
  <reference>
    <citation>Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology. 1997 Nov;26(5):1338-42.</citation>
    <PMID>9362381</PMID>
  </reference>
  <reference>
    <citation>Ikeda K, Kobayashi M, Saitoh S, Someya T, Hosaka T, Akuta N, Suzuki Y, Suzuki F, Tsubota A, Arase Y, Kumada H. Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy: long-term follow up of a pilot study. J Gastroenterol Hepatol. 2005 Jan;20(1):95-102.</citation>
    <PMID>15610453</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 21, 2019</study_first_submitted>
  <study_first_submitted_qc>May 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>June 19, 2019</last_update_submitted>
  <last_update_submitted_qc>June 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Lin Bingliang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

